Questions | Reviews ***

We don't currently have any questions about Dacarbazine.

Dacarbazine (DTIC-Dome)
(dah- KAR-bah-zeen)
Pregnancy Category: C DTIC DTIC-Dome Imidazole Carboxamide (Abbreviation: DTIC) (Rx)

Classification: Antineoplastic, alkylating agent

See Also: See also Antineoplastic Agents and Alkylating Agents .

Action/Kinetics: Mechanisms of action: alkylation by an activated carbonium ion, antimetabolite to inhibit DNA and RNA synthesis, and alkylation by combining with protein sulfhydryl groups. Is cell-cycle nonspecific. t 1/2, biphasic, initial, 19 min; terminal, 5 hr. The t 1/2 is increased to 55 min and 7.2 hr in those with renal and hepatic dysfunction. Probably localizes in liver. Limited amounts (14% of plasma level) enter CSF. Approximately 40% of drug excreted in urine unchanged within 6 hr. Secreted through the kidney tubules rather than filtered through the glomeruli.

Uses: Metastatic malignant melanoma. Hodgkin's disease (with other agents). Investigational: In combination with cyclophosphamide and vincristine for malignant pheochromocytoma; in combination with tamoxifen for metastatic malignant melanoma.

Contraindications: Lactation.

Special Concerns: Dosage not established in children.

Additional Side Effects Hematologic: Hemopoietic depression, especially leukopenia and thrombocytopenia which may cause death. GI: N&V (more than 90% of clients within 1 hr after initial administration, which persists for 12-48 hr), anorexia, diarrhea. Dermatologic: Erythematous and urticarial rashes, photosensitivity reactions, alopecia, facial flushing, paresthesia. Miscellaneous: Flu-like syndrome, including fever, myalgia, and malaise. Hepatotoxicity, hypersensitivity, anaphylaxis.

Laboratory Test Alterations: AST, ALT, and other enzymes.

Overdose Management: Treatment: Monitor blood cell counts; supportive treatment.

How Supplied: Injection: 10 mg/mL

?IV Only Malignant melanoma.
2-4.5 mg/kg/day for 10 days; may be repeated at 4-week intervals; or 250 mg/m 2/day for 5 days; may be repeated at 3-week intervals.
Hodgkin's disease.
150 mg/m 2/day for 5 days in combination with other drugs, and repeated q 4 weeks; or, 375 mg/m 2 on day 1, with other drugs and repeated q 15 days.

Dacarbazine Ratings

Overall Rating:



(based on 2 reviews)



Ease of Use:


Overall Satisfaction:




Sure is quiet in here. You can write the first review of Dacarbazine.